Table 3.
Average maximal CCA-IMT and average annual maximal CCA-IMT progression in people with and without diabetes
| Average max CCA-IMT (mm) |
Average annual max CCA-IMT progression (mm/year) |
|||||
|---|---|---|---|---|---|---|
| Cohort | Diabetes, mean (SD) | No diabetes, mean (SD) | Difference, mean (SE)& | Diabetes, mean (SD) | No diabetes, mean (SD) | Difference, mean (SE)& |
| AIR | 1.04 (0.17) | 0.98 (0.16) | 0.062 (0.046) | 0.006 (0.062) | 0.014 (0.042) | −0.008 (0.013) |
| ARIC | 0.83 (0.16) | 0.76 (0.13) | 0.054 (0.004) | 0.015 (0.055) | 0.015 (0.044) | 0.000 (0.002) |
| BHS | 0.91 (0.22) | 0.75 (0.12) | 0.092 (0.019) | −0.006 (0.102) | 0.001 (0.048) | −0.009 (0.008) |
| Bruneck | 1.02 (0.15) | 0.95 (0.18) | 0.004 (0.022) | 0.022 (0.032) | 0.028 (0.027) | −0.004 (0.004) |
| CCCC | 0.79 (0.20) | 0.73 (0.18) | 0.032 (0.015) | 0.023 (0.048) | 0.019 (0.049) | 0.004 (0.004) |
| CHS1 | 1.09 (0.20) | 1.03 (0.18) | 0.050 (0.007) | 0.013 (0.070) | 0.009 (0.060) | 0.004 (0.002) |
| CHS2 | 1.11 (0.18) | 1.09 (0.19) | 0.020 (0.024) | −0.006 (0.035) | 0.004 (0.035) | −0.010 (0.005) |
| CMCS | 0.92 (0.29) | 0.88 (0.25) | 0.043 (0.034) | 0.051 (0.053) | 0.053 (0.057) | −0.002 (0.008) |
| DIWA | 1.07 (0.23) | 0.98 (0.18) | 0.088 (0.030) | 0.001 (0.026) | 0.008 (0.026) | −0.007 (0.004) |
| KIHD | 1.08 (0.17) | 1.06 (0.22) | 0.004 (0.038) | 0.063 (0.041) | 0.066 (0.049) | −0.002 (0.009) |
| NOMAS/INVEST | 0.93 (0.09) | 0.94 (0.09) | −0.002 (0.001) | 0.008 (0.029) | 0.009 (0.032) | −0.002 (0.003) |
| PIVUS | 1.12 (0.17) | 1.06 (0.17) | 0.056 (0.025) | 0.020 (0.043) | 0.015 (0.036) | 0.005 (0.005) |
| PLIC | 0.82 (0.13) | 0.73 (0.15) | 0.032 (0.015) | 0.003 (0.038) | 0.009 (0.043) | −0.006 (0.005) |
| Rotterdam | 1.08 (0.17) | 1.01 (0.16) | 0.047 (0.013) | 0.012 (0.020) | 0.016 (0.023) | −0.004 (0.002) |
| SHIP | 0.98 (0.20) | 0.89 (0.19) | 0.036 (0.011) | 0.002 (0.032) | 0.000 (0.031) | 0.001 (0.002) |
| Tromsø | 1.09 (0.21) | 0.97 (0.18) | 0.082 (0.017) | 0.014 (0.043) | 0.005 (0.025) | 0.009 (0.003) |
| Combined (CI 95%)* | 0.96 (0.22) | 0.87 (0.20) | 0.046 (0.041–0.051) | 0.013 (0.055) | 0.015 (0.043) | −0.000 (−0.002 to 0.001) |
Max CCA-IMT is not available in CAPS, Edinburgh Artery Study (EAS), Estudio epidemiológico sobre enfermedades y factores de riesgo cardiovasculares en ancianos españoles (EPICARDIAN), INVADE, and Salzburg Atherosclerosis Prevention program in subjects at High Individual Risk (SAPHIR). AIR, Atherosclerosis and Insulin Resistance study; CCCC, Chin-Shan Community Cardiovascular Cohort; CMCS, Chinese Multi-provincial Cohort Study; DIWA, Diabetes, Impaired glucose tolerance in Women and Atherosclerosis; KIHD, Kuopio Ischaemic Heart Disease study; PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors; PLIC, Progression of Lesions in the Intima of the Carotid; Rotterdam, Rotterdam Study; Tromsø, Tromsø Study.
&Adjusted for age and sex by multiple regression.
*Combined means and SDs weighted by sample size; differences between people with and without diabetes combined by random-effects meta-analysis.